Oxipurinol

Oxipurinol
Names
	Preferred IUPAC name 1,2-Dihydropyrazolo[4,3-e]pyrimidine-4,6-dione
	Systematic IUPAC name 1H,2H,4H,5H,6H-pyrazolo[3,4-d]pyrimidine-4,6-dione
	Other names 1H,2H,5H-pyrazolo[3,4-d]pyrimidine-4,6-dione; Alloxanthine
Identifiers
CAS Number	2465-59-0;
3D model (JSmol)	Interactive image;
Beilstein Reference	139956
ChEBI	CHEBI:28315;
ChEMBL	ChEMBL859 ;
ChemSpider	4483;
ECHA InfoCard	100.017.792
EC Number	219-570-9;
KEGG	C07599;
MeSH	Oxypurinol
PubChem CID	4644;
UNII	G97OZE5068;
CompTox Dashboard (EPA)	DTXSID4035209 ;
	InChI InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11) Key: HXNFUBHNUDHIGC-UHFFFAOYSA-N;
	SMILES O=C1NC(=O)C2=CNNC2=N1;
Properties
Chemical formula	C5H4N4O2
Molar mass	152.11086
Appearance	white crystals
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

Oxipurinol (INN, or oxypurinol USAN) is an inhibitor of xanthine oxidase.[1] It is an active metabolite of allopurinol and it is cleared renally.[2] In cases of renal disease, this metabolite will accumulate to toxic levels. By inhibiting xanthine oxidase, it reduces uric acid production. High serum uric acid levels may result in gout, kidney stones, and other medical conditions.

References

Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O (2012). "The pharmacokinetics of oxypurinol in people with gout". British Journal of Clinical Pharmacology. 74 (3): 477–489. doi:10.1111/j.1365-2125.2012.04207.x. PMC 3477349. PMID 22300439.
Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H (1968). "Renal clearance of oxipurinol, the chief metabolite of allopurinol". The American Journal of Medicine. 45 (1): 69–77. doi:10.1016/0002-9343(68)90008-9. PMID 5658870.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O (2012). "The pharmacokinetics of oxypurinol in people with gout". British Journal of Clinical Pharmacology. 74 (3): 477–489. doi:10.1111/j.1365-2125.2012.04207.x. PMC 3477349. PMID 22300439.

[2] Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H (1968). "Renal clearance of oxipurinol, the chief metabolite of allopurinol". The American Journal of Medicine. 45 (1): 69–77. doi:10.1016/0002-9343(68)90008-9. PMID 5658870.